Global Information
회사소개 | 문의 | 위시리스트

특발성 폐섬유화증(IPF) : 역학 예측(-2030년)

Idiopathic Pulmonary Fibrosis (IPF) - Epidemiology Forecast to 2030

리서치사 DelveInsight Business Research LLP
발행일 2020년 02월 상품 코드 534893
페이지 정보 영문 110 Pages
가격
US $ 3,750 ₩ 4,566,000 PDF by E-mail (Single User License)
US $ 7,500 ₩ 9,132,000 PDF by E-mail (Site License)
US $ 11,250 ₩ 13,697,000 PDF by E-mail (Global License)


특발성 폐섬유화증(IPF) : 역학 예측(-2030년) Idiopathic Pulmonary Fibrosis (IPF) - Epidemiology Forecast to 2030
발행일 : 2020년 02월 페이지 정보 : 영문 110 Pages

특발성 폐섬유화증(IPF)은 희귀한 만성 진행성 섬유화 간질성 폐렴이며, 중년 이상 성인에게 영향을 미치는 것으로 밝혀졌습니다. 그리고, 시간과 흐름에 따라 불가역적으로 간질이 두꺼워지면서 폐조직, 특히 허파꽈리에 영향을 줍니다. 또, 혈액 속의 산소량이 제한되기 때문에 걷기나 일상생활시에 호흡곤란을 느끼는 일이 있습니다. 주요 7개국(미국, 영국, 독일, 프랑스, 이탈리아, 스페인, 일본)의 특발성 폐섬유화증(IPF) 총환자수는 2017년 22만 9,170명에 이른 것으로 추정됩니다.

주요 7개국(미국, 영국, 독일, 프랑스, 이탈리아, 스페인)의 특발성 폐섬유화증(IPF: Idiopathic Pulmonary Fibrosis) 시장을 조사했으며, 시장 및 질환 개요, 전체 및 국가별 역학적 예측, 중증도·성별·연령층별 환자수 추이와 예측, 충족되지 않은 요구, 현재 치료법 등에 대해 정리했습니다.

목차

제1장 프리미엄 인사이트

제2장 특발성 폐섬유화증(IPF) 시장 개요

  • 시장 점유율과 분포(실적)
  • 시장 점유율과 분포(예측)

제3장 질환의 배경과 개요 : 특발성 폐섬유화증(IPF)

  • 서론
  • 특발성 폐섬유화증(IPF)에 관한 통계
  • 특발성 폐섬유화증(IPF)의 병기 분류
  • 위험요인과 원인
  • 증상
  • 병인
  • 진단

제4장 역학과 환자 인구

  • 주요 조사결과
  • 주요 7개국의 특발성 폐섬유화증(IPF) 환자수

제5장 특발성 폐섬유화증(IPF)의 역학 : 국가별

  • 미국
    • 특발성 폐섬유화증(IPF) 환자수
    • 특발성 폐섬유화증(IPF) 환자수 : 중증도별
    • 특발성 폐섬유화증(IPF) 환자수 : 성별
    • 특발성 폐섬유화증(IPF) 환자수 : 연령층별
  • 유럽 5개국
    • 특발성 폐섬유화증(IPF) 환자수
    • 독일
    • 프랑스
    • 이탈리아
    • 영국
    • 스페인
  • 일본
    • 특발성 폐섬유화증(IPF) 환자수

제6장 현재 치료법

  • ATS/ERS/JRS/ALAT 임상 진료 가이드라인 : 특발성 폐섬유화증(IPF) 치료(2011 임상 진료 가이드라인 업데이트)
  • Patient Journey

제7장 충족되지 않은 요구

제8장 부록

  • 조사 방법

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight에 대해

LSH 20.02.12

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Table 1: Expected 1-year probability of death in patients with idiopathic pulmonary fibrosis
  • Table 2: The GAP (Gender, Age, and Physiology) score
  • Table 3: The GAP index and staging system
  • Table 4: High resolution computed tomography criteria for up pattern
  • Table 5: 7MM, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 6: The United States, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 7: The United States, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Table 8: The United States, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 9: The United States, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 10: EU5, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 11: Germany, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 12: Germany, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Table 13: Germany, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 14: Germany, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 15: France, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 16: France, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Table 17: France, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 18: France, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 19: Italy, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 20: Italy, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Table 21: Italy, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 22: Italy, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 23: The United Kingdom, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 24: The United Kingdom, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Table 25: The United Kingdom, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 26: The United Kingdom, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 27: Spain, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 28: Spain, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Table 29: Spain, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 30: Spain, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 31: Japan, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 32: Japan, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Table 33: Japan, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Table 34: Japan, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030

List of Figures

  • Figure 1: Risk factors associated with IPF
  • Figure 2: IPF associated clubbing of the fingertips
  • Figure 3: Stages of the pathogenesis of IPF
  • Figure 4: A schematic representing the current model for the pathogenesis of IPF
  • Figure 5: Possible mechanisms of fibrogenesis in IPF
  • Figure 6: Chest radiograph of a patient with IPF showing bilateral lower lobe reticular opacities (red circles)
  • Figure 7: Subpleural honeycombing in IPF diagnosed patients
  • Figure 8: ATS/ERS criteria for the diagnosis of idiopathic pulmonary fibrosis in the absence of surgical lung biopsy (2000).
  • Figure 9: Combination of high-resolution computed tomography and surgical lung biopsy for the diagnosis of IPF (requires multidisciplinary discussion)
  • Figure 10: Diagnostic algorithm for idiopathic pulmonary fibrosis (IPF). Patients with suspected IPF
  • Figure 11: 7MM, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 12: The United States, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 13: The United States, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Figure 14: The United States, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 15: The United States, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 16: EU5, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 17: Germany, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 18: Germany, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Figure 19: Germany, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 20: Germany, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 21: France, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 22: France, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Figure 23: France, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 24: France, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 25: Italy, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 26: Italy, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Figure 27: Italy, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 28: Italy, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 29: The United Kingdom, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 30: The United Kingdom, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Figure 31: The United Kingdom, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 32: The United Kingdom, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 33: Spain, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 34: Spain, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Figure 35: Spain, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 36: Spain, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 37: Japan, Historical & Forecasted Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 38: Japan, Historical & Forecasted Prevalence of Idiopathic Pulmonary Fibrosis by severity, 2017-2030
  • Figure 39: Japan, Gender-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 40: Japan, Age-specific Idiopathic Pulmonary Fibrosis Prevalence, 2017-2030
  • Figure 41: Suggested Algorithm for IPF Treatment
  • Figure 42: Unmet Needs of IPF

DelveInsight's 'Idiopathic Pulmonary Fibrosis (IPF)- Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Idiopathic Pulmonary Fibrosis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2030.

Idiopathic Pulmonary Fibrosis Disease Understanding

Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia which is found to affect the middle-aged and older adults; and affects lung tissue (alveoli in particular) by either thickening, stiffening, or persistent and progressive scarring (fibrosis) which increases irreversibly over time. If an individual has IPF, scarring affects the air sacs, limiting the amount of oxygen that gets into the blood. With less oxygen in the blood, one can get breathlessness from everyday activities, like walking. This group of lung disorders is also known as 'Diffuse Parenchymal Lung Diseases,' which is characterized by a broader umbrella of 'Interstitial Lung Diseases (IDLs).

Idiopathic Pulmonary Fibrosis Epidemiology

The Idiopathic Pulmonary Fibrosis (IPF) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. The epidemiology data for Idiopathic Pulmonary Fibrosis are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Idiopathic Pulmonary Fibrosis Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Prevalent cases of IPF, Age-specific cases, Prevalence by severity and Gender-specific cases of IPF) scenario of Idiopathic Pulmonary Fibrosis (IPF)in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total number of prevalent cases of Idiopathic Pulmonary Fibrosis (IPF) in 7 MM was found to be 229,170, in the year 2017.

Report Scope

  • The report covers detailed overview of Idiopathic Pulmonary Fibrosis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Idiopathic Pulmonary Fibrosis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by Prevalent cases, Age-specific cases, Prevalence by severity and Gender-specific cases of Idiopathic Pulmonary Fibrosis in 7MM

Key strengths

  • 11 Year Forecast of Idiopathic Pulmonary Fibrosis epidemiology
  • 7MM Coverage
  • Total prevalent cases of IPF
  • Incident Cases according to segmentation: Prevalent cases, Age-specific cases, Prevalence by severity and Gender-specific cases of IPF

Key assessments

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Idiopathic Pulmonary Fibrosis Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Idiopathic Pulmonary Fibrosis in 2017
  • 2.2. Market Share (%) Distribution of Idiopathic Pulmonary Fibrosis in 2028

3. Disease Background and Overview: Idiopathic Pulmonary Fibrosis (IPF)

  • 3.1. Introduction
  • 3.2. Statistics about Idiopathic Pulmonary Fibrosis
  • 3.3. Staging of Idiopathic Pulmonary Fibrosis
  • 3.4. Risk Factors and Disease Causes
  • 3.5. Symptoms
  • 3.6. Pathogenesis
  • 3.7. Diagnosis

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Prevalent Population of Idiopathic Pulmonary Fibrosis

5. Country Wise-Epidemiology of Idiopathic Pulmonary Fibrosis

  • 5.1. United States
    • 5.1.1. Prevalent cases of Idiopathic Pulmonary Fibrosis in the United States
    • 5.1.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
    • 5.1.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
    • 5.1.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
  • 5.2. EU5
    • 5.2.1. Prevalent Population of Idiopathic Pulmonary Fibrosis in EU5
    • 5.2.2. Germany
      • 5.2.2.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
      • 5.2.2.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
      • 5.2.2.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
      • 5.2.2.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
    • 5.2.3. France
      • 5.2.3.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
      • 5.2.3.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
      • 5.2.3.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
      • 5.2.3.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
    • 5.2.4. Italy
      • 5.2.4.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
      • 5.2.4.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
      • 5.2.4.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
      • 5.2.4.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
    • 5.2.5. United Kingdom
      • 5.2.5.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
      • 5.2.5.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
      • 5.2.5.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
      • 5.2.5.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
    • 5.2.6. Spain
      • 5.2.6.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
      • 5.2.6.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
      • 5.2.6.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
      • 5.2.6.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence
  • 5.3. Japan
    • 5.3.1. Prevalent Population of Idiopathic Pulmonary Fibrosis
    • 5.3.2. Prevalent Population of Idiopathic Pulmonary Fibrosis by severity
    • 5.3.3. Gender-specific Idiopathic Pulmonary Fibrosis Prevalence
    • 5.3.4. Age-specific Idiopathic Pulmonary Fibrosis Prevalence

6. Current Treatment Practices

  • 6.1. ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis (An Update of 2011 Clinical Practice Guideline)
  • 6.2. Patient Journey

7. Unmet Needs

8. Appendix

  • 8.1. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

Back to Top
전화 문의
F A Q